Journal Watch · Clinical Pharmacology & Therapeutics · 2026
Safety, Tolerability, and Pharmacokinetics of GMDTC for Cadmium Poisoning: A Randomized Phase 1a/1b Trial.
These findings support GMDTC as a novel therapeutic agent to enhance cadmium elimination in humans.
TL;DR
These findings support GMDTC as a novel therapeutic agent to enhance cadmium elimination in humans.
Key findings
- No dose-limiting toxicities were observed, and 169 adverse events were recorded across all cohorts, with no apparent dose-related pattern or serious safety concerns.
- GMDTC exhibited dose-proportional pharmacokinetics, with a half-life of 1.25-2.63 hour, and urinary cadmium excretion increased dose-dependently within 24 hour after treatment.
- In Phase 1b, GMDTC significantly increased 24-hour urinary cadmium excretion, which positively correlated with the administered dose.
- GMDTC was well tolerated at doses up to 2000 mg, with no serious adverse events or dose-limiting toxicities.
- These findings support GMDTC as a novel therapeutic agent to enhance cadmium elimination in humans.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Thereafter, Phase 1b randomized 30 participants with elevated urinary cadmium into three groups (500, 1000, or 2000 mg GMDTC), who received daily injections for 3 consecutive days, with placebo controls included in each group. During the trial, safety and tolerability were monitored for 72 hour following administration. The primary endpoints included dose-limiting toxicity, urinary cadmium excretion, pharmacokinetic parameters, and efficacy of GMDTC. In Phase 1a, 76 participants completed the study.
Full abstract (original)
Background: Cadmium exposure causes serious health consequences; however, there is no clinically approved antidote for cadmium poisoning. This Phase 1a/1b trial aimed to investigate safety, tolerability, and pharmacokinetics of Sodium (S)-2-(dithiocarboxylato((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl) amino)-4-(methylthio) butanoate (GMDTC), a novel chelating agent proved to eliminate cadmium through renal glucose transporters. This first-in-human study included two phases. Phase 1a was a randomized, double-blind, single-center, single-dose, dose escalation trial, in which 78 eligible healthy participants aged 18-65 years were assigned to cohorts receiving GMDTC (250, 500, 850, 1200, 1600, or 2000 mg) or placebo.
What they did: Thereafter, Phase 1b randomized 30 participants with elevated urinary cadmium into three groups (500, 1000, or 2000 mg GMDTC), who received daily injections for 3 consecutive days, with placebo controls included in each group. During the trial, safety and tolerability were monitored for 72 hour following administration. The primary endpoints included dose-limiting toxicity, urinary cadmium excretion, pharmacokinetic parameters, and efficacy of GMDTC. In Phase 1a, 76 participants completed the study.
Results & conclusions: No dose-limiting toxicities were observed, and 169 adverse events were recorded across all cohorts, with no apparent dose-related pattern or serious safety concerns. GMDTC exhibited dose-proportional pharmacokinetics, with a half-life of 1.25-2.63 hour, and urinary cadmium excretion increased dose-dependently within 24 hour after treatment. In Phase 1b, GMDTC significantly increased 24-hour urinary cadmium excretion, which positively correlated with the administered dose. GMDTC was well tolerated at doses up to 2000 mg, with no serious adverse events or dose-limiting toxicities. These findings support GMDTC as a novel therapeutic agent to enhance cadmium elimination in humans.
Abstract © the authors / Clinical Pharmacology & Therapeutics (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1002/cpt.70275 · PubMed 41915445.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking Clinical Pharmacology & Therapeutics for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Clinical Pharmacology & Therapeutics study find?
These findings support GMDTC as a novel therapeutic agent to enhance cadmium elimination in humans.
What type of study is this?
It is a randomised / controlled clinical trial, published in Clinical Pharmacology & Therapeutics in 2026. Thereafter, Phase 1b randomized 30 participants with elevated urinary cadmium into three groups (500, 1000, or 2000 mg GMDTC), who received daily injections for 3 consecutive days, with placebo controls included in each group.
Where can I read the original paper?
The original is at the publisher via DOI 10.1002/cpt.70275. PubMed ID: 41915445. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/safety-tolerability-and-pharmacokinetics-of-gmdtc-for-cadmium-poisoning-t70275/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides